Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species Post published:June 24, 2021 Post category:Press Release
Silo Wellness Debuts Marley One, the First Global Functional and Psychedelic Mushroom Brand, in Collaboration with the Bob Marley Family Post published:June 24, 2021 Post category:Press Release
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004 Post published:June 24, 2021 Post category:Press Release
Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board Post published:June 23, 2021 Post category:Press Release
MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues Post published:June 23, 2021 Post category:Press Release
Awakn Life Sciences to Commence Trading on the NEO Exchange under the Symbol ‘AWKN’ Post published:June 23, 2021 Post category:Press Release
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board Post published:June 23, 2021 Post category:Press Release
COMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme Post published:June 23, 2021 Post category:Press Release
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie Post published:June 22, 2021 Post category:Press Release
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study Post published:June 22, 2021 Post category:Press Release